MONTEREY PARK, CA – March 12, 2009 – GeneFluidics, Inc., a biotech company that designs, markets and manufactures automated testing equipment based on proprietary electrochemical-based molecular analysis and an advanced engineering platform, today announced that the National Institute of Allergy and Infectious Diseases (NIAID), through the National Institutes of Health (NIH) has funded a biotechnology and clinical research grant to the Liao Laboratory at Stanford University. The Liao Laboratory will work closely with Stanford University and GeneFluidics to develop a next-generation pathogen identification system and validate it using clinical samples.
The specific aims of the four-year project are to develop a microfluidic sample processing and detection system using electrokinetic processing and GeneFluidics’ proprietary electrochemical biosensor, and to validate the system with clinical urine samples, to achieve molecular pathogen identification in less than 15 minutes, with a detection sensitivity of 1,000 CFU/mL.
The principal investigator for the project is Dr. Joseph Liao, Associate Professor of Urology at Stanford University and Chief of Urology at the Veterans Affair Hospital in Palo Alto.
“We look forward to continuing our collaboration with Dr. Liao and his team at the Palo Alto Veterans Institute for Research and Stanford University,” said Vincent Gau, CEO and President of GeneFluidics. “We are excited about the opportunity to move ahead with our integrated microfluidic biosensor technology and validate it with clinical samples.”
About the National Institutes of Health
The National Institutes of Health (NIH) is an agency of the U.S. Department of Health and Human Services, and is the Federal focal point of health and medical research. NIH is the leading supporter of biomedical research in the world.
About the National Institute of Allergy and Infectious Diseases (NIAID)
The NIAID is one of the 27 institutes and centers that make up the NIH. NIAID’s mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.
About the Liao Lab at Stanford University
The Liao Lab is a research laboratory that focuses on translating molecular diagnostics for urological diseases from bench to bedside. Interfacing biology, engineering, medicine, and surgery, the Liao Lab aims to translate molecular biosensing and imaging technologies to clinics with the goal of transforming the diagnosis and treatment of urological infections and cancers that are some of the most common and expensive human diseases.
GeneFluidics was incorporated in 2000 to develop a fast, accurate, and simple testing system for improving worldwide health. By integrating novel bionano electrochemical technologies, the company’s revolutionary sensor platform enables bioassays to be performed in under an hour with sensitivity to picogram/ml concentrations for immunoassays and femtomolar concentrations for genetic assays, without the use of PCR.
For more information on GeneFluidics, contact:
Vincent Gau, President/CEO
845 Meridian Street, Irwindale, CA 91010
Phone: 626 263-3060
NOTE: Contact information on this page for GeneFluidics was updated from the original press release, which used the previous address and phone number for the company.